MX2023001049A - Composiciones y métodos para tratar infecciones virales. - Google Patents
Composiciones y métodos para tratar infecciones virales.Info
- Publication number
- MX2023001049A MX2023001049A MX2023001049A MX2023001049A MX2023001049A MX 2023001049 A MX2023001049 A MX 2023001049A MX 2023001049 A MX2023001049 A MX 2023001049A MX 2023001049 A MX2023001049 A MX 2023001049A MX 2023001049 A MX2023001049 A MX 2023001049A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- nucleic acids
- compositions
- methods
- viral infections
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2007849 | 2020-07-24 | ||
| PCT/US2021/043077 WO2022020782A1 (en) | 2020-07-24 | 2021-07-23 | Compositions and methods for treating viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001049A true MX2023001049A (es) | 2023-04-11 |
Family
ID=77398656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001049A MX2023001049A (es) | 2020-07-24 | 2021-07-23 | Composiciones y métodos para tratar infecciones virales. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230304010A1 (enExample) |
| EP (1) | EP4185602A1 (enExample) |
| JP (1) | JP2023536436A (enExample) |
| CN (1) | CN116724059A (enExample) |
| AU (1) | AU2021314336A1 (enExample) |
| CA (1) | CA3190101A1 (enExample) |
| MX (1) | MX2023001049A (enExample) |
| WO (1) | WO2022020782A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3955967A4 (en) | 2019-04-17 | 2023-06-07 | Aadigen, LLC | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF MOLECULES |
| WO2024187121A1 (en) * | 2023-03-08 | 2024-09-12 | Red Queen Therapeutics, Inc. | Combination therapies comprising stabilized sars-cov-2 peptides |
| WO2024187174A2 (en) | 2023-03-09 | 2024-09-12 | Aadigen, Llc | Compositions for treating cancer with kras mutations and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050113298A1 (en) * | 2003-09-15 | 2005-05-26 | The Brigham And Women's Hospital, Inc. | Receptor binding peptides derived from the SARS S protein |
| US7514530B2 (en) | 2004-04-26 | 2009-04-07 | Centre National De La Recherche Scientifique | Peptide carrier for delivering siRNA into mammalian cells |
| US7579318B2 (en) | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2012137036A1 (en) | 2011-04-04 | 2012-10-11 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053880A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053881A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053879A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053882A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| MX387665B (es) | 2014-12-24 | 2025-03-18 | Aadigen Llc | Péptidos, complejos, moléculas de carga y nanopartículas que contienen los mismos. |
| CA3025523A1 (en) * | 2016-05-27 | 2017-11-30 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of genome-editing molecules |
| AU2018313940A1 (en) * | 2017-08-10 | 2020-03-05 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of virus |
-
2021
- 2021-07-23 WO PCT/US2021/043077 patent/WO2022020782A1/en not_active Ceased
- 2021-07-23 JP JP2023504816A patent/JP2023536436A/ja active Pending
- 2021-07-23 CN CN202180062573.5A patent/CN116724059A/zh active Pending
- 2021-07-23 CA CA3190101A patent/CA3190101A1/en active Pending
- 2021-07-23 EP EP21756120.8A patent/EP4185602A1/en active Pending
- 2021-07-23 MX MX2023001049A patent/MX2023001049A/es unknown
- 2021-07-23 AU AU2021314336A patent/AU2021314336A1/en not_active Abandoned
- 2021-07-23 US US18/017,644 patent/US20230304010A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230304010A1 (en) | 2023-09-28 |
| AU2021314336A1 (en) | 2023-03-09 |
| WO2022020782A1 (en) | 2022-01-27 |
| JP2023536436A (ja) | 2023-08-25 |
| CN116724059A (zh) | 2023-09-08 |
| CA3190101A1 (en) | 2022-01-27 |
| EP4185602A1 (en) | 2023-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001049A (es) | Composiciones y métodos para tratar infecciones virales. | |
| EP4445902A3 (en) | Diacylglycerol kinase modulating compounds | |
| EA202092808A1 (ru) | Вакцины на основе наночастиц с новыми структурными компонентами | |
| WO2021046549A8 (en) | Compositions and methods for the treatment of viral infections | |
| WO2020252393A8 (en) | Compositions and methods for the treatment of human immunodeficiency virus | |
| PH12021550822A1 (en) | Compositions and methods for the treatment of viral infections | |
| WO2017019891A3 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| SG195194A1 (en) | Nanogels | |
| PH12022552125A1 (en) | Stabilized soluble pre-fusion rsv f proteins | |
| WO2016183366A3 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
| WO2017156311A3 (en) | Combination vectors and methods for treating cancer | |
| MX2022014598A (es) | Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno. | |
| EP4567109A3 (en) | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome | |
| WO2021046398A3 (en) | Combination antiviral therapy for measles | |
| WO2009120339A3 (en) | Vectors for delivering disease neutralizing agents | |
| MX2021012604A (es) | Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas. | |
| ZA202202180B (en) | Engineered hcv e2 immunogens and related vaccine compositions | |
| WO2008064072A3 (en) | Anti-tsg101 antibodies and their uses for treatment of viral infections | |
| WO2023021098A3 (en) | Pharmaceutical composition comprising nanoparticles for the targeted delivery of antigens | |
| WO2021061707A8 (en) | Compositions and methods for modulating apolipoprotein b (apob) gene expression | |
| MX2019013874A (es) | Peptidos y sus usos como agentes antivirales. | |
| PH12022550240A1 (en) | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof | |
| WO2020053742A3 (en) | Anti-hla-hbv peptide antibodies | |
| WO2023150375A3 (en) | Methods and compositions for treating covid infections | |
| WO2021081515A3 (en) | Compositions and methods for the treatment of human immunodeficiency virus |